MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Prednisone | Prednisolone

Selected References:

  • Carmichael SL, et al. 2007. Maternal corticosteroid use & orofacial clefts. Am J Obstet Gynecol; 197(6):585.e1-585.e7.
  • Constantinescu S, et al. 2014. Breast-feeding after transplantation. Best Pract Res Clin Obstet Gynaecol; 28(8):1163-73.
  • Fitzsimons R, et al. 1986. Outcome of pregnancy in women requiring corticosteroids for severe asthma. J Allergy Clin Immunol 78(2):349-53.
  • Gomaa MF, et al. 2014. Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cerlls and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet; 290:757–762.
  • Gur C, et al. 2004. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol; 18(1):93-101.
  • Hendry WF, et al. 1990. Comparison of prednisolone and placebo in subfertile men with antibodies to spermatozoa. Lancet; 335:85-8.
  • Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 168:1393-9.
  • Man YA, et al. 2009. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 60(11):3196-3206.
  • Marzec I, et al. 2021. Pregnancy after liver transplant: maternal and perinatal outcomes. BMC Pregnancy Childbirth; 21: 627.
  • McGuire E. 2012. Sudden loss of milk supply following high-dose triamcinolone (Kenacort) injection. Breastfeed Rev. 20:32–4.
  • Nørgård B, et al. 2007. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol; 102:1406-13.
  • Nyberg G, et al. 1998. Breast-feeding during treatment with cyclosporine. Transplantation 65:253-5.
  • Ost L, et al. 1985. Prednisolone excretion in human milk. J Pediatr; 106:1008-11.
  • Palmsten K, et al. 2020. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford). 59(6):1262-1271.
  • Park-Wyllie L, et al. 2000. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6):385-92.
  • Petri M, et al. 1992. The Hopkins Lupus Pregnancy Center: 1987-1991 update. Am J Reprod Immunol; 28(3-4):188-91.
  • Pradat P, et al. 2003. First trimester exposure to corticosteroids & oral clefts. Birth Defects Res A Clin Mol Teratol 67(12):968-70.
  • Rodríguez-Pinilla E & Martínez-Frías ML. 1998. Corticosteroids during pregnancy & oral clefts: a case-control study. Teratology 58(1):2-5.
  • Ryu RJ, et al. 2018. Prednisone pharmacokinetics during pregnancy & lactation. J Clin Pharmacol; 58(9):1223-1232.
  • Skuladottir H, et al. 2014. Corticosteroid use and risk of orofacial clefts. Birth Defects Res (Part A) 100: 499-506.
  • Silver RK, et al. 1993. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody – positive obstetrics patients. Am J Obstet Gynecol 169(6):1411-7.
  • Tata LJ, et al. 2008. Effects of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. Thorax 63(11):981-87.
  • Van Zutphen AR, et al, National Birth Defects Prevention Study. 2015. Maternal asthma medication use during pregnancy and risk of congenital heart defects. Birth Defects Res A Clin Mol Teratol 103(11):951-61.
  • Viktil KK, et al. 2012. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 41(3):196-2012.
  • Xu L, et al. 2009. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring. Transpl Immunol; 22(1-2):28-31.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.